1 |
Khan MS, Mohapatra S, Gupta V, Ali A, Naseef PP, Kurunian MS, Alshadidi AAF, Alam MS, Mirza MA, Iqbal Z. Potential of Lipid-Based Nanocarriers against Two Major Barriers to Drug Delivery—Skin and Blood–Brain Barrier. Membranes 2023;13:343. [DOI: 10.3390/membranes13030343] [Reference Citation Analysis]
|
2 |
Nouri Z, Sajadimajd S, Hoseinzadeh L, Bahrami G, Arkan E, Moradi S, Abdi F, Farzaei MH. Neuroprotective effect of naringenin-loaded solid lipid nanoparticles against streptozocin-induced neurotoxicity through autophagy blockage. J Food Biochem 2022;46:e14408. [PMID: 36129161 DOI: 10.1111/jfbc.14408] [Reference Citation Analysis]
|
3 |
Sharma S, Hafeez A, Usmani SA. Nanoformulation approaches of naringenin- an updated review on leveraging pharmaceutical and preclinical attributes from the bioactive. Journal of Drug Delivery Science and Technology 2022;76:103724. [DOI: 10.1016/j.jddst.2022.103724] [Reference Citation Analysis]
|
4 |
Sousa F. Brain-Targeted Drug Delivery. Pharmaceutics 2022;14:1835. [DOI: 10.3390/pharmaceutics14091835] [Reference Citation Analysis]
|
5 |
Alhalmi A, Amin S, Khan Z, Beg S, Al kamaly O, Saleh A, Kohli K. Nanostructured Lipid Carrier-Based Codelivery of Raloxifene and Naringin: Formulation, Optimization, In Vitro, Ex Vivo, In Vivo Assessment, and Acute Toxicity Studies. Pharmaceutics 2022;14:1771. [DOI: 10.3390/pharmaceutics14091771] [Reference Citation Analysis]
|
6 |
Abdelhameed AH, Abdelhafez WA, Saleh K, Mohamed MS. Formulation, optimization, and in-vivo evaluation of nanostructured lipid carriers loaded with Fexofenadine HCL for oral delivery. Journal of Drug Delivery Science and Technology 2022;74:103607. [DOI: 10.1016/j.jddst.2022.103607] [Reference Citation Analysis]
|